Evidence map›Paper›PMID 39386028›Full record

ArticleFrontiers in pharmacology2024

Muscarinic receptor drug trihexyphenidyl can alter growth of mesenchymal glioblastoma

Renfei Du, Ahmed Y Sanin, Wenjie Shi, Bing Huang, Ann-Christin Nickel, Andres Vargas-Toscano, Shuran Huo, Thomas Nickl-Jockschat, Claudia A Dumitru, Wei Hu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Renfei DuChifeng Municipal Hospital, Chifeng, China.
Ahmed Y SaninMolecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany.
Wenjie ShiMolecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany.
Bing HuangFORM, Frankfurt Oral Regenerative Medicine, Clinic for Maxillofacial and Plastic Surgery, Goethe University, Frankfurt Am Main, Germany.
Ann-Christin NickelClinic for Neurosurgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.
Andres Vargas-ToscanoClinic for Neurosurgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.
Shuran HuoChifeng Cancer Hospital, Chifeng, China.
Thomas Nickl-JockschatDepartment of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Germany.
Claudia A DumitruClinic for Neurosurgery, Medical Faculty and University Hospital Magdeburg, Otto von Guericke University, Magdeburg, Germany.
Wei HuChifeng Municipal Hospital, Chifeng, China.
Siyu DuanChifeng Municipal Hospital, Chifeng, China.
I Erol SandalciogluClinic for Neurosurgery, Medical Faculty and University Hospital Magdeburg, Otto von Guericke University, Magdeburg, Germany.
Roland S CronerMolecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany.
Joshua AlcanizExperimental Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany.
Wolfgang WaltherExperimental Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany.
Carsten BerndtClinic for Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.
Ulf D KahlertMolecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most commonly occurring and most aggressive primary brain tumor. Transcriptomics-based tumor subtype classification has established the mesenchymal lineage of GBM (MES-GBM) as cancers with particular aggressive behavior and high levels of therapy resistance. Previously it was show that Trihexyphenidyl (THP), a market approved M1 muscarinic receptor-targeting oral drug can suppress proliferation and survival of GBM stem cells from the classical transcriptomic subtype. In a series of

Indexed as

cystathionine beta-synthasedrug repurposingglioblastomamesenchymal transformationtrihexyphenidyl

Identifiers

PMID39386028
PMCPMC11461351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.